DominiciMLe BlancKMuellerI. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-317.
2.
EnglishAJonesEACorscaddenD. A comparative assessment of cartilage and joint fat pad as a potential source of cells for autologous therapy development in knee osteoarthritis. Rheumatology (Oxford). 2007;46:1676-1683.
3.
GianniniSBudaRCavalloM. Cartilage repair evolution in post-traumatic osteochondral lesions of the talus: from open field autologous chondrocyte to bone-marrow-derived cells transplantation. Injury. 2010;41:1196-1203.
4.
GianniniSBudaRVanniniFCavalloMGrigoloB. One-step bone marrow-derived cell transplantation in talar osteochondral lesions. Clin Orthop Relat Res. 2009;467:3307-3320.
5.
GimbleJMBunnellBAChiuESGuilakF. Concise review: adipose-derived stromal vascular fraction cells and stem cells: let’s not get lost in translation. Stem Cells. 2011;29:749-754.
6.
KimYSParkEHKimYCKohYG. Clinical outcomes of mesenchymal stem cell injection with arthroscopic treatment in older patients with osteochonral lesions of the talus. Am J Sports Med. 2013;41(5):1090-1099.
7.
WickhamMQEricksonGRGimbleJMVailTPGuilakF. Multipotent stromal cells derived from the infrapatellar fat pad of the knee. Clin Orthop Relat Res. 2003;412:196-212.
8.
ZukPAZhuMMizunoH. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001;7:211-228.
